Simulect induction significantly decreases CMV infection in kidney recipients compared to OKT3.
Kode
R K
RK
Division of Transplantation, MCP Hahnemann University, Philadelphia, Pennsylvania, USA.
Kumar
A M
AM
Pankewycz
O
O
Damask
A M
AM
Seirka
D
D
Lam
A
A
Phillips
K
K
Ardron
M
M
Brezin
J
J
Chvala
R
R
Kumar
M S
MS
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000401:mortality; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000401:mortality; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab